ebselen has been researched along with GRL-0617 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V | 1 |
| Hu, Y; Jadhav, P; Tan, B; Tan, H; Wang, J | 1 |
| Chen, N; Hao, H; Lai, M; Li, Z; Liao, Y; Wan, N; Wu, N; Xiao, Y; Yan, H; Ye, H; Yu, W; Zhao, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
3 review(s) available for ebselen and GRL-0617
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
Topics: Antiviral Agents; Coronavirus Papain-Like Proteases; COVID-19 Drug Treatment; Humans; Pandemics; Protease Inhibitors; SARS-CoV-2 | 2022 |
2 other study(ies) available for ebselen and GRL-0617
| Article | Year |
|---|---|
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Papain; Peptide Hydrolases; Protease Inhibitors; Rats; SARS-CoV-2; Viral Nonstructural Proteins; Viral Proteases | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |